Last kr28.60 SEK
Change Today -0.40 / -1.38%
Volume 5.3K
HMED On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
As of 12:00 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

hansa medical research ab (HMED) Snapshot

Open
kr28.90
Previous Close
kr29.00
Day High
kr28.90
Day Low
kr27.70
52 Week High
12/11/14 - kr32.10
52 Week Low
12/20/13 - kr7.71
Market Cap
741.6M
Average Volume 10 Days
22.6K
EPS TTM
kr-0.87
Shares Outstanding
25.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HANSA MEDICAL RESEARCH AB (HMED)

Related News

No related news articles were found.

hansa medical research ab (HMED) Related Businessweek News

No Related Businessweek News Found

hansa medical research ab (HMED) Details

Hansa Medical AB, a clinical stage drug development company, focuses on developing novel immunomodulatory enzymes for the treatment of rare and acute conditions characterized by pathogenic antibodies. The company develops IdeS, an enzyme that is in Phase II study for the treatment of inactivating anti-HLA antibodies in sensitized patients prior to surgery, thereby enabling kidney transplantation; and EndoS, an enzyme, which is in preclinical discovery phase to treat autoimmune diseases and other inflammatory conditions, such as autoimmune hemolysis, systemic lupus, and glomerulonephritis. It is also involved in developing HBP-assay, a diagnostic method to predict severe sepsis in patients well before the onset of devastating clinical symptoms. Hansa Medical AB was founded in 2001 and is headquartered in Lund, Sweden.

Founded in 2001

hansa medical research ab (HMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hansa medical research ab (HMED) Key Developments

Hansa Medical Announces Board and Executive Changes

The Board of Directors of Hansa Medical has appointed Fredrik Lindgren to CEO. Fredrik Lindgren is a member of the board of Hansa Medical since 2012 and takes up the position as CEO with immediate effect. Fredrik Lindgren replaces Emanuel Björne who remains with the company in a commercial position. He has been CEO of Karo Bio AB and Biolin Scientific AB, and has executive experience from Midsona AB and Active Biotech AB. He is currently a member of the board of ProstaLund AB and Exini Diagnostics AB. Upon assuming the position as CEO, Fredrik Lindgren will resign from the position as member of the board of Hansa Medical.

Hansa Medical Appoints Birgit Stattin Norinder as New Chairman

The board of directors Of Hansa Medical has named Birgit Stattin Norinder as its new chairman. Birgit Stattin Norinder is a member of the board of directors since 2012. She has extensive experience from international Pharmaceutical and Biotechnology companies. She has held several senior Research and Development positions in Swedish, UK and US based Pharmaceutical companies including Pharmacia & Upjohn, Glaxo Group Research and Astra Research Centre. She has been Chief Executive Officer and Chairman of Prolifix Ltd. Birgit Stattin Norinder has also held several board and chairman.

Hansa Medical Announces Demise of Bo Håkansson, Founder and Chairman

The Hansa Medical founder and chairman Bo Håkansson passed away during following a motocross accident at his estate, Farstorp, outside Eslöv, Sweden. He was the large shareholder in Hansa Medical through his company Farstorps Gård AB.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HMED:SS kr28.60 SEK -0.40

HMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HMED.
View Industry Companies
 

Industry Analysis

HMED

Industry Average

Valuation HMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 136.0x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 149.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANSA MEDICAL RESEARCH AB, please visit www.hansamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.